Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer.
Jimenez JE, Abdelhafez A, Mittendorf EA, Elshafeey N, Yung JP, Litton JK, Adrada BE, Candelaria RP, White J, Thompson AM, Huo L, Wei P, Tripathy D, Valero V, Yam C, Hazle JD, Moulder SL, Yang WT, Rauch GM. Jimenez JE, et al. Among authors: moulder sl. Eur J Radiol. 2022 Apr;149:110220. doi: 10.1016/j.ejrad.2022.110220. Epub 2022 Feb 15. Eur J Radiol. 2022. PMID: 35193025
Advances in the treatment of breast cancer.
Moulder S, Hortobagyi GN. Moulder S, et al. Clin Pharmacol Ther. 2008 Jan;83(1):26-36. doi: 10.1038/sj.clpt.6100449. Epub 2007 Dec 19. Clin Pharmacol Ther. 2008. PMID: 18091763 Review.
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
Moulder SL, Symmans WF, Booser DJ, Madden TL, Lipsanen C, Yuan L, Brewster AM, Cristofanilli M, Hunt KK, Buchholz TA, Zwiebel J, Valero V, Hortobagyi GN, Esteva FJ. Moulder SL, et al. Clin Cancer Res. 2008 Dec 1;14(23):7909-16. doi: 10.1158/1078-0432.CCR-08-1104. Clin Cancer Res. 2008. PMID: 19047121 Free PMC article. Clinical Trial.
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms.
Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Wheler JJ, et al. Oncotarget. 2014 May 15;5(9):2349-54. doi: 10.18632/oncotarget.1946. Oncotarget. 2014. PMID: 24811890 Free PMC article.
Leptomeningeal disease and breast cancer: the importance of tumor subtype.
Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, Smith B, Valero V, Hortobagyi GN, Melhem-Bertrandt A. Abouharb S, et al. Among authors: moulder sl. Breast Cancer Res Treat. 2014 Aug;146(3):477-86. doi: 10.1007/s10549-014-3054-z. Epub 2014 Jul 20. Breast Cancer Res Treat. 2014. PMID: 25038877 Review.
Gene signature-guided dasatinib therapy in metastatic breast cancer.
Pusztai L, Moulder S, Altan M, Kwiatkowski D, Valero V, Ueno NT, Esteva FJ, Avritscher R, Qi Y, Strauss L, Hortobagyi GN, Hatzis C, Symmans WF. Pusztai L, et al. Clin Cancer Res. 2014 Oct 15;20(20):5265-71. doi: 10.1158/1078-0432.CCR-14-0800. Epub 2014 Aug 29. Clin Cancer Res. 2014. PMID: 25172932 Clinical Trial.
157 results